These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29727106)

  • 1. Efficacy of intravitreal aflibercept in patients with exudative age-related macular degeneration.
    Dolar-Szczasny J; swiEch-zuBilewicz A; Mackiewicz J
    Klin Oczna; 2016 Sep; 117(4):221-224. PubMed ID: 29727106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.
    Sawada T; Wang X; Sawada O; Saishin Y; Ohji M
    Clin Exp Ophthalmol; 2018 Jan; 46(1):46-53. PubMed ID: 28621038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial utilization of aflibercept in exudative age-related macular degeneration.
    Cho H; Weber ML; Shah CP; Heier JS
    Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Visual and anatomical outcomes of three intravitreal aflibercept injections in eyes with neovascular form of age-related macular degeneration].
    Kałuiny JJ; Majer A; Jaworowska-Cieślińska I
    Klin Oczna; 2015; 117(1):9-13. PubMed ID: 26349151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    de Oliveira Dias JR; de Andrade GC; Kniggendorf VF; Novais EA; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
    Retina; 2017 Aug; 37(8):1499-1507. PubMed ID: 27798520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.
    Mansour AM; Chhablani J; Antonios RS; Yogi R; Younis MH; Dakroub R; Chahine H
    Br J Ophthalmol; 2016 Dec; 100(12):1629-1633. PubMed ID: 27030277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
    Ohji M; Takahashi K; Okada AA; Kobayashi M; Matsuda Y; Terano Y;
    Adv Ther; 2020 Mar; 37(3):1173-1187. PubMed ID: 32016788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M; Kano M; Itagaki K; Sekiryu T
    Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
    Hall LB; Zebardast N; Huang JJ; Adelman RA
    J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
    Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
    J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
    Chan CK; Jain A; Sadda S; Varshney N
    Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab and aflibercept for the treatment of exudative age-related macular degeneration.
    Selid PD; Jundt MC; Fortney AC; Beal JR
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(4):275-81. PubMed ID: 25037009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.